Several experimental findings already pointed to CB1R as therapeutic target to treat altered feeding behavior and obesity [30,34,41,42], due to the hyperphagic role of this receptor, and the possible exploitation of its pharmacological blockade, as recently reviewed [43]. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.